Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology*Biology*Physics. 2002;53(5):1111–6.
2.
Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2008;70(4):1124–9.
3.
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, et al. Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate. JAMA. 2005;294(10):1233.
4.
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology*Biology*Physics. 2002;53(5):1097–105.
5.
Viani GA, Stefano EJ, Afonso SL. Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials. International Journal of Radiation Oncology*Biology*Physics. 2009;74(5):1405–18.
6.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). International Journal of Radiation Oncology*Biology*Physics. 1995;31(5):1341–6.
7.
Poggi MM, Gant DA, Sewchand W, Warlick WB. Marker seed migration in prostate localization. International Journal of Radiation Oncology*Biology*Physics. 2003;56(5):1248–51.
8.
Litzenberg D, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, et al. Daily prostate targeting using implanted radiopaque markers. International Journal of Radiation Oncology*Biology*Physics. 2002;52(3):699–703.
9.
Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. Pre-treatment risk stratification of prostate cancer patients: A critical review. Canadian Urological Association Journal. 2012;6(2):121–7.
10.
Jemal A, Center MM, DeSantis C, Ward EM. Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiology, Biomarkers & Prevention. 2010;19(8):1893–907.
11.
Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy. Journal of Clinical Oncology. 2006;24(13):1990–6.
12.
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2008;70(1):67–74.
13.
Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of Intensity-Modulated Radiotherapy in Reducing Toxicity in Dose Escalation for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2009;73(3):685–91.
14.
Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. Radiotherapy and Oncology. 2002;64(3):239–50.
15.
Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management. Cancer. 91(12):2302–14.
16.
NCCN Guidelines Version 1.2018. Prostate cancerJanuar. 2018;
17.
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine. 2009;360(13):1320–8.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
